我们可以用新型的直接作用抗病毒药治愈乙肝病毒吗？

StephenW

Liver Int. 2020 Feb;40 Suppl 1:27-34. doi: 10.1111/liv.14364.
Can we cure hepatitis B virus with novel direct-acting antivirals?
Martinez MG1,2, Villeret F1,2, Testoni B1,2, Zoulim F1,2,3,4,5.
Author information

1
    Cancer Research Center of Lyon (CRCL), Lyon, France.
2
    INSERM, U1052, Lyon, France.
3
    Hospices Civils de Lyon (HCL), Lyon, France.
4
    University of Lyon, UMR_S1052, UCBL, Lyon, France.
5
    Institut Universitaire de France (IUF), Paris, France.

Abstract

Current treatments against chronic hepatitis B (CHB) include pegylated interferon alpha (Peg-IFNα) and nucleos(t)ide analogs (NAs), the latter targeting the viral retrotranscriptase, thus inhibiting de novo viral production. Although these therapies control infection and improve the patient's quality of life, they do not cure HBV-infected hepatocytes. A complete HBV cure is currently not possible because of the presence of the stable DNA intermediate covalently closed circular DNA (cccDNA). Current efforts are focused on achieving a functional cure, defined by the loss of Hepatitis B surface antigen (HBsAg) and undetectable HBV DNA levels in serum, and on exploring novel targets and molecules that are in the pipeline for early clinical trials. The likelihood of achieving a long-lasting functional cure, with no rebound after therapy cessation, is higher using combination therapies targeting different steps in the hepatitis B virus (HBV) replication cycle. Novel treatments and their combinations are discussed for their potential to cure HBV infection, as well as exciting new technologies that could directly target cccDNA and cure without killing the infected cells.

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
KEYWORDS:

cccDNA; HBV cure; chronic hepatitis B; direct acting antiviral

PMID:
    32077597
DOI:
    10.1111/liv.14364

StephenW

肝内科。 2020 Feb; 40补编1：27-34。 doi：10.1111 / liv.14364。
我们可以用新型的直接作用抗病毒药治愈乙肝病毒吗？
马丁内斯MG1,2，Villeret F1,2，Testoni B1,2，Zoulim F1,2,3,4,5。
作者信息

1个
    法国里昂癌症研究中心（CRCL）。
2
    INSERM，U1052，里昂，法国。
3
    法国里昂市的利比里亚平民医院（HCL）。
4
    里昂大学，UMR_S1052，UCBL，里昂，法国。
5
    法国巴黎大学研究所（IUF），法国巴黎。

抽象

目前针对慢性乙型肝炎（CHB）的治疗方法包括聚乙二醇化干扰素α（Peg-IFNα）和核苷酸（t）ide类似物（NAs），后者靶向病毒逆转录酶，从而抑制了从头产生病毒。尽管这些疗法可控制感染并改善患者的生活质量，但它们不能治愈HBV感染的肝细胞。由于存在稳定的DNA中间体共价闭合环状DNA（cccDNA），目前无法完全治愈HBV。当前的工作集中在实现功能性治愈（由乙型肝炎表面抗原（HBsAg）的丧失和血清中无法检测到的HBV DNA水平定义）上，以及在探索可用于早期临床试验的新型靶标和分子。使用针对乙型肝炎病毒（HBV）复制周期不同步骤的联合疗法，实现持久功能治愈，停止治疗后无反弹的可能性更高。讨论了治疗HBV感染的新方法及其组合，以及可以直接靶向cccDNA并治愈而又不杀死感染细胞的令人兴奋的新技术。

©2020 John Wiley＆Sons A / S。由John Wiley＆Sons Ltd.发布。
关键字：

cccDNA; HBV治愈；慢性乙型肝炎直接作用抗病毒药

PMID：
    32077597
DOI：
    10.1111 / liv.14364

StephenW

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.14364